Glaucoma is one of the leading causes of blindness, and there is an ongoing need for new therapies. Recent studies indicate that cell transplantation using Müller glia may be beneficial, but there is a need for novel sources of cells to provide therapeutic benefit. In this study, we have isolated Müller glia from retinal organoids formed by human induced pluripotent stem cells (hiPSCs) in vitro and have shown their ability to partially restore visual function in rats depleted of retinal ganglion cells by NMDA. Based on the present results, we suggest that Müller glia derived from retinal organoids formed by hiPSC may provide an attractive source of cells for human retinal therapies, to prevent and treat vision loss caused by retinal degenerative conditions. Stem Cells Translational Medicine 2019;8:775&784 Purified populations of Müller glial cells were isolated from retinal organoids derived from human iPSC. Intra‐vitreal transplantation of these cells into rat eyes depleted of RGC by NMDA caused partial restoration of visual function, as assessed by improvement of the retinal electrophysiological responses. These findings highlight the potential of iPSC as a potential source of therapeutic cells for retinal degeneration.